Please select the option that best describes you:

Would you consider omitting concurrent chemoradiation for a patient with stage III EGFR-mutant NSCLC and initiating treatment with osimertinib instead?  



Answer from: Radiation Oncologist at Academic Institution
Comments
Medical Oncologist at Henry Ford Cancer Institute/Henry Ford Hospital
Agree. However, the question is whether starting w...
Radiation Oncologist at Yale School of Medicine
Interesting study idea! I would worry a bit about ...
Radiation Oncologist at Wake Forest School of Medicine
Smith et al., PMID 36923158  Concurrent osim...
Medical Oncologist at Kaiser Permanente
I want to add my 2 cents and the reason for my que...
Medical Oncologist at Los Angeles VA Medical Center
Dr. @Chunhui Fang, you can consider Dr. @Tejas Pat...
Sign in or Register to read more

Answer from: Radiation Oncologist at Community Practice
Sign in or Register to read more